Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

The first is Nuplazid, which was approved in 2016 and remains the only approved treatment for hallucinations and delusions ...

It had an excellent phase 1b dataset with a very strong treatment effect on the primary ... leading on-market brands in ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

The Parkinson’s disease (PD) therapeutic landscape is heavily ... With current treatments largely focused on motor symptoms, ...

Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

While Parkinson’s disease (PD) has a large and highly generalised ... the market due to their efficacy against core PD motor ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on ACIU stock, giving a Buy rating yesterday. Marc Goodman has given ...

Pipeline Updates NLRP3 Portfolio VTX3232 (CNS-penetrant NLRP3 Inhibitor): We initiated a Phase 2a trial of VTX3232 in participants with early Parkinson’s disease ... CNS-penetrant NLRP3 inhibitor for ...